Women who receive false-positive results from routine breast cancer screenings may experience a low quality of life and feelings of anxiety for at least one year, according to a study published online Dec. 20 in the British Journal of Surgery.
TUESDAY, Jan. 25 (HealthDay News) -- Women who receive false-positive results from routine breast cancer screenings may experience a low quality of life and feelings of anxiety for at least one year, according to a study published online Dec. 20 in the British Journal of Surgery.
Alida F.W. van der Steeg, M.D., from the St. Elisabeth Hospital in Lilburg, Netherlands, and colleagues conducted a longitudinal study, measuring the quality of life of 385 women diagnosed with breast disease, between September 2002 and January 2007. Of these women, 152 were correctly diagnosed with breast cancer and 233 women had false-positive mammogram results. Anxiety and quality of life were assessed in these women before diagnosis and during the 12 months following.
The researchers found that significantly more histological biopsies were required in the false-positive group. Almost 60 percent of the false-positive group revisited the outpatient clinic during the first year. Women in the false-positive group with the highest scores on trait anxiety scored lowest on the quality-of-life assessment, and they reported more feelings of anxiety, compared to women with lower trait anxiety scores in either the false-positive or breast cancer groups.
"Women deserve more balanced information to help them choose whether or not to accept an invitation for screening mammography. This should not only focus on the supposed benefits, but should include potential side effects, such as increased feelings of anxiety," the authors write.
HP-hMG stimulation reduces OHSS risk in high responder patients
October 25th 2024A recent study found that highly purified human menotropin significantly lowers the risk of ovarian hyperstimulation syndrome compared to recombinant follicle stimulating hormone, highlighting the benefits of protocol individualization based on gonadotropin type.
Read More